Form 4: Evolent Health Director Jill Smith Receives Equity Grant

Evolent Health, Inc. Director Jill D. Smith was granted 23,137 restricted stock units as part of her compensation.

Summary

• Jill D. Smith, a Director of Evolent Health, Inc. (EVH), acquired 23,137 shares of Class A Common Stock.
• The transaction occurred on January 2, 2026, at a price of $0 per share, indicating a grant of restricted stock units.
• These restricted stock units were granted pursuant to the Amended and Restated Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan.
• The securities will vest on the earlier of January 2, 2027, or the date of the Company's 2026 annual meeting, contingent on Ms. Smith's continued service.

Sentiment

Score: 6

Explanation: The grant of restricted stock units to a director aligns management interests with shareholders, which is generally viewed positively, though it also represents a minor dilution.

Positives

• The grant of restricted stock units to a director aligns management's interests with those of shareholders, promoting long-term value creation.
• The compensation structure utilizes an existing, approved incentive compensation plan, indicating a consistent approach to executive and director remuneration.

Negatives

• The issuance of new equity, even restricted stock units, can lead to minor dilution for existing shareholders upon vesting.

Future Outlook

The filing primarily details a past transaction and future vesting schedule for restricted stock units, rather than providing a broad future outlook for the company's performance or strategy.

Industry Context

This Form 4 filing is a routine disclosure of insider compensation, common across all publicly traded companies. It does not provide specific insights into Evolent Health's competitive position or broader industry trends in healthcare technology and services.

Corporate Governance

Related Party Transactions

• Grant of 23,137 restricted stock units to Jill D. Smith, a Director of Evolent Health, Inc., as part of her compensation package.

Stakeholder Impact

• Shareholders: Minor potential for dilution upon vesting of the restricted stock units.
• Directors: Increased alignment of personal financial interests with the long-term performance of the company.

Next Steps

• The restricted stock units will vest on the earlier of January 2, 2027, or the date of the Company's 2026 annual meeting, provided Ms. Smith remains in service.

Key Dates

Keywords

Evolent Health, EVH, Form 4, Insider Transaction, Restricted Stock Units, Equity Grant, Director Compensation, Corporate Governance